We identified through the EdU assay that the proliferative ability of HCC cells was significantly reduced after sorafenib treatment, with a more pronounced effect observed in the HCC cells from the si-TMEM39b group (Figs. 5A–5D). This evidence concerns the gene TMEM39B and hepatocellular carcinoma.